Business
Schrödinger Reports Fourth Quarter and Full-Year 2025 Financial Results
2025 Total Revenue of $256 Million 2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million Strong Balance Sheet Supports Path to Positive
About this update from Schrodinger, Inc.
[{"type":"text","content":"\n2025 Total Revenue of $256 Million\n\n\n2025 Software Revenue of $200 Million; 2025 Software ACV of $198 Million\n\n\nStrong Balance Sheet Supports Path to Positive Adjusted EBITDA by Year-End 2028\n\n\nAccelerating Transition to Ratable, Hosted Software Revenue\n\n\n NEW YORK--(BUSINESS WIRE)--\nSchrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the fourth quarter and full-year ended December 31, 2025, and provided its 2026 outlook and 2028 financial objectives.\n\n\n\"Schrödinger’s performance in 2025, marked by 23% total revenue growth and 11% software revenue growth, is a testament to the resilience of our business and the unique value we provide,\" said Ramy Farid, Ph.D., chief executive officer of Schrödinger. “While the drug discovery AI landscape is expanding rapidly, we differentiate ourselves by consistently delivering outsized real-world impact, validated by continued robust customer engagement, high customer retention, and a strong track record of highly differentiated development candidates across our collaborative and internal therapeutics portfolio. Our success is enabled by our transformative platform that integrates ground-truth, physics-based simulation with leading-edge AI and machine learning. Looking ahead to 2026, we are poised to scale our impact through new platform enhancements and the commercial launch of our predictive toxicology solution.”\n\n\nFull Year 2025 Financial Highlights (comparisons are to full year 2024, unless otherwise noted)\n\n\n\nTotal revenue was $255.9 million, a 23.3% increase.\n\n\n\nSoftware revenue was $199.5 million, a 10.6% increase.\n\n\n\nDrug discovery revenue was $56.4 million compared to $27.2 million.\n\n\n\nSoftware gross margin was 74%.\n\n\n\nOperating expenses were $309.5 million, a 9.3% decrease.\n\n\n\nOther income, which includes gains/losses on equity investments, changes in fair value of such investments and interest income/expense, was $64.6 million.\n\n\n\nNet loss for the full year was $103.3 million, compared to $187.1 million.\n\n\n\nAt December 31, 2025, Schrödinger had cash, cash equivalents, restricted cash and marketable securities of approximately $402.3 million, compared to approximately $367.5 million at December 31, 2024.\n\n\n\nFourth Quarter 2025 Financial Highlights (comparisons are to fourth quarter 2024, unless otherwise no...